BALTIMORE, Sep 08, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas will report its financial results for the second quarter ended June 30, 2006, after the close o...  

August 4, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today the pricing of its initial public offering of 3,500,000 shares of its common stock at a price of $11.00 per share. All of the shares are being sold by the Company. Up to an additional 525,000 shares have been made available to the underwriters to cover over-allotm...  

May 12, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today that the Company has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been de...  

April 5, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today that it has completed enrollment in a human clinical trial designed to evaluate the safety and preliminary effectiveness of its universal adult stem cell drug candidate Provacel™, being developed to treat patients suffering from heart attacks. A total of 53 pat...  

BALTIMORE, Maryland – December 20, 2005 - Osiris Therapeutics, Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for PROCHYMAL™, an adult stem cell product under investigation for the treatment of acute Graft vs. Host Disease (GVHD). Orphan drug status provides market exclusiv...